CJC-1295 (with DAC)

CJC-1295 (with DAC) is a research-use-only synthetic peptide analog derived from the growth hormone-releasing hormone (GHRH) family. It is widely used in academic, pharmaceutical, and veterinary research environments to investigate mechanisms related to growth hormone regulation, endocrine signaling, and metabolic physiology. This compound is provided strictly for laboratory research applications and is not intended for therapeutic, diagnostic, or cosmetic use.

Research Context

CJC-1295 was developed to enhance the stability and biological activity of naturally occurring growth hormone-releasing hormone. The addition of Drug Affinity Complex (DAC) technology allows the peptide to bind to circulating albumin, significantly extending its half-life in experimental systems. Because of this prolonged activity, researchers frequently use CJC-1295 (with DAC) to study long-duration growth hormone stimulation and the regulatory pathways associated with endocrine signaling.

Research Overview

CJC-1295 (with DAC) functions by binding to growth hormone-releasing hormone receptors in the pituitary gland. This interaction stimulates the endogenous release of growth hormone and subsequently influences downstream signaling involving insulin-like growth factor-1 (IGF-1). In laboratory studies, the peptide has been utilized to examine endocrine feedback loops, metabolic regulation, and hormonal signaling networks. Its extended activity profile makes it particularly valuable for studying sustained hormonal modulation in controlled experimental settings.

Key Research Focus Areas

• Endocrine Signaling: Investigation of growth hormone-releasing hormone receptor activation and the downstream pathways involved in hormonal regulation.
• Metabolic Studies: Examination of how prolonged growth hormone stimulation influences metabolic activity and energy regulation in experimental models.
• IGF-1 Pathway Research: Analysis of the interaction between growth hormone secretion and insulin-like growth factor signaling mechanisms.
• Extended Peptide Activity: Study of long-acting peptide analogs and their pharmacological properties in controlled laboratory environments.
• Pharmacokinetic Evaluation: Investigation of absorption, distribution, metabolism, and elimination characteristics associated with DAC-modified peptides.

Safety and Compliance Note

CJC-1295 (with DAC) is supplied exclusively for scientific research and must be handled by qualified professionals in controlled laboratory settings. It is not approved for therapeutic, diagnostic, or veterinary applications. All research should be conducted in accordance with institutional safety policies, regulatory standards, and applicable laws governing peptide research materials.

For research use only. Not for human or animal consumption.